Mendus AB (publ)

Thank you everybody for joining. Welcome to the Q4 finance and business update of Mendes on behalf of myself and our CFO Lotte Verm.

Hi everyone.

Let's start with a summary of Q4. We presented continued positive data of our phase two trial, the advanced two trial in MRD positive AML at ASH, the American Society of Hematology Conference end of last year. The updated clinical development strategy in acute myeloid leukemia and AML aligns with the evolution of first-time treatment. And we will also say a few words about how that first-time treatment is shaping up, including recent updates that took place at the ASH conference last December. Our clinical trial strategy is established to not only position Fetidansel in AML, but also as an active immunotherapy in chronic myeloid leukemia or CML. We have established together with our manufacturing partner, Northex Biologics, a large scale GMP production, which will support our late stage clinical development and in the end also registration and commercial launch of the product. It was a very significant milestone that we accomplished in Q4. to make sure that we have a good balance between the costs of the company and the additional trials that we anticipate to start in 2026. We have completed a reorganization, which included the reduction of staff, including the reduction of the management team. And we financed the company through a directed issue with significant insider support from members of the board and myself and, of course, our larger shareholders, combined with a 50 million loan facility that we closed with Venya, on which Lotta will comment when we do the financial update. The long-term survival data of the Allison trial in ovarian cancer, which we presented first at ESCO mid-last year, but then also updated to your survival in Q4, confirmed the safety and feasibility of ididenza as a potential combination therapy in high-risk ovarian cancer. Let me move to the financial slide and let Lotta summarize the financial situation.